Drug Neurology

Torpenz

Payments companies reported to CMS as associated with Torpenz. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$21Kassociated payments (2023-2025)
227clinicians with associated payments
2companies reporting

By year

2024 $15K
2025 $6,135

Payments reported as associated with Torpenz, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology With Special Qualifications In Child Neurology $10K
Neurology (Psychiatry & Neurology) $2,257
Pediatric Nephrology $1,660
Neurodevelopmental Disabilities (Pediatrics) $1,566
Pediatrics (Nurse Practitioner) $1,152
Epilepsy $906

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Torpenz

These are the largest totals companies reported as associated with Torpenz. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
James Wheless Memphis, TN Neurology With Special Qualifications In Child Neurology $1,859.96
Steven Sparagana Dallas, TX Neurology With Special Qualifications In Child Neurology $1,650.00
Lyndsay Harshman Iowa City, IA Pediatric Nephrology $1,575.00
Douglas Smith Roseville, MN Neurology With Special Qualifications In Child Neurology $1,350.00
Derek Bauer Rochester, NY Neurology (Psychiatry & Neurology) $1,350.00
Ryan Gill Baltimore, MD Neurodevelopmental Disabilities (Pediatrics) $1,350.00
Stephanie Randle Seattle, WA Neurology With Special Qualifications In Child Neurology $1,350.00
Dave Shahani Fort Worth, TX Neurology With Special Qualifications In Child Neurology $1,275.00
Lai Brooks Memphis, TN Nurse Practitioner $240.05
Sarah Weatherspoon Memphis, TN Epilepsy $229.67

Prescribed Torpenz?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.